Phase II Randomized Double-Blinded Placebo-Controlled study that will evaluate the efficacy safety and tolerability of natalizumab as adjunctive therapy in adult subjects with drug-resistant focal epilepsy.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
